An Unsurprising Pipeline Failure

Eli Lilly (NYSE: LLY  ) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.

The patent cliff cometh
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 09, 2013, at 11:11 AM, HungryHunter12 wrote:

    I agree with the risk of banks dominating ETFs in developing markets. How does one find the consumer, health care and other attractive companies in those markets?

Add your comment.

DocumentId: 2244719, ~/Articles/ArticleHandler.aspx, 7/23/2014 3:13:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement